Cicatrix Clinical Trial
Official title:
A Prospective Study to Compare the Cosmetic Results of Sutures With Different Absorption Rates for Lower Abdominal Incision
The previous studies have demonstrated that wedge excision combined modified buried vertical mattress suture (WE-MBVMS) provides better aesthetic outcomes than traditional ways. Prolonged tension reduction is crucial in WE-MBVMS suppressing scar, while suture used during WE-MBVMS decided the length of tension reducing time to a certain degree. However, presently surgeons select suture for WE-MBVMS mostly according to their personal preference and clinical experience and clinical comparative evidence exposing the best suture for desired cosmetic outcome is lacking. Here, investigators purposed to establish a feasibility trial comparing the scars left by WE-MBVMS using sutures with different tension holding time. This is a feasibility, single-center RCT with 35 patients aiming to compare the scar of the hypogastric incision sutured by three different-absorption-rate sutures with WE-MBVMS. The incision induced by donating skin grafts is evenly divided into three segments, each segment randomly uses one of three different sutures randomly allocated by the SAS (V.9.4) statistical software. The feasibility of this study will be assessed by the primary outcomes, including patient and clinician enrolment refusal as well as their reasons, reasons for ineligibility, recruitment ratio, retention and withdrawal at each follow-up point (1, 3, and 6 months), reasons for withdrawal, integrity of collected data and adverse event rates. Secondary outcome measures of the cosmetic outcome of scar will help shape future fully powered RCT by formulating the sample size.
Status | Recruiting |
Enrollment | 35 |
Est. completion date | October 31, 2023 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - surgical incisions need to be closed after skin gotten; - incisions at least 10 cm in length; - patients aged between18 and 60 years old. Exclusion Criteria: - chronic diseases, like diabetes, chronic kidney disease, malignant neoplasms and severe malnutrition; - pregnancy; - inability to return for the follow-up visit; - unwillingness to provide informed consent; - inability to read or speak Chinese. |
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital Xi'an Jiaotong University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Visual Analogue Scale (VAS) | As a 10cm line with 0 presenting the worst and 10 presenting the best overall satisfaction, the score of VAS is collected by patients placing a vertical mark on the VAS. | 1 month after the surgery | |
Primary | Visual Analogue Scale (VAS) | As a 10cm line with 0 presenting the worst and 10 presenting the best overall satisfaction, the score of VAS is collected by patients placing a vertical mark on the VAS. | 3 month after the surgery | |
Primary | Visual Analogue Scale (VAS) | As a 10cm line with 0 presenting the worst and 10 presenting the best overall satisfaction, the score of VAS is collected by patients placing a vertical mark on the VAS. | 6 month after the surgery | |
Primary | Patient Scar Assessment Scale (PSAS) | Six domains including pain, itching, colour, pliability, thickness and relief, are contained in the PSAS. | 1 month after the surgery | |
Primary | Patient Scar Assessment Scale (PSAS) | Six domains including pain, itching, colour, pliability, thickness and relief, are contained in the PSAS. | 3 month after the surgery | |
Primary | Patient Scar Assessment Scale (PSAS) | Six domains including pain, itching, colour, pliability, thickness and relief, are contained in the PSAS. | 6 month after the surgery | |
Primary | Observer Scar Assessment Scale (OSAS) | Six domains including pain, itching, colour, pliability, thickness and relief, are contained in the OSAS. | 1 month after the surgery | |
Primary | Observer Scar Assessment Scale (OSAS) | Six domains including pain, itching, colour, pliability, thickness and relief, are contained in the OSAS. | 3 month after the surgery | |
Primary | Observer Scar Assessment Scale (OSAS) | Six domains including pain, itching, colour, pliability, thickness and relief, are contained in the OSAS. | 6 month after the surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02672956 -
Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results
|
N/A | |
Completed |
NCT02645773 -
Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring
|
N/A | |
Completed |
NCT00629811 -
Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women
|
Phase 2 | |
Completed |
NCT00977951 -
Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT00847795 -
Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03213548 -
Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty
|
N/A | |
Recruiting |
NCT05377723 -
Abdominal Scar Improvement in Microsurgical Breast Reconstruction
|
N/A | |
Active, not recruiting |
NCT01976260 -
A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars
|
N/A | |
Terminated |
NCT00432328 -
Juvista (Avotermin) in Breast Reduction Surgery Scars
|
Phase 2 | |
Completed |
NCT00594581 -
Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males
|
Phase 2 | |
Completed |
NCT00984503 -
Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
|
Phase 2 | |
Recruiting |
NCT04420442 -
Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars
|
N/A | |
Completed |
NCT02772289 -
Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
|
Phase 2 | |
Completed |
NCT00430326 -
Juvista (Avotermin) in Scars Following Varicose Vein Removal
|
Phase 2 | |
Completed |
NCT00847925 -
Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT02985151 -
Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy
|
N/A | |
Completed |
NCT02340325 -
FS2 Safety and Tolerability Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT00432211 -
Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
|
Phase 2 | |
Completed |
NCT00978302 -
Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)
|
Phase 1 | |
Withdrawn |
NCT04034615 -
The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
|
Phase 2 |